The embryo and early fetus, regardless of genetic sex (i.e., 46,XX or 46,XY), are bipotential (i.e., sex indifferent) with respect to their possible sexual differentiation, having the anatomic and biochemical apparatus necessary for both male and female development. For normal male differentiation to occur, a succession of genetic and hormonal signals must be intact and occur normally.47 The classic teaching is that there is an innate tendency of the embryo and early fetus to differentiate along female lines; that is, female differentiation occurs if the signals for male differentiation are absent. However, evidence is growing that describes an active process involved in female differentiation.88 The biopotential gonad begins to differentiate at 7 weeks of gestation under the direction of both sex and autosomal chromosome gene products, which primarily act as transcription factors. The presence of the SRY gene on the Y chromosome causes the bipotential gonad to differentiate as a testis, and male phenotypic development follows. The presence of one, two, or more X chromosomes does not alter this process; however, the presence of more than one X chromosome (e.g., 47,XXY syndrome) results in eventual meiotic failure, loss of germ cells, and infertility. Candidate genes for an X-linked female determining factor are being investigated.3 Y chromosome fetuses that fail to undergo testicular differentiation are believed to experience the same gonadal changes to form streak gonads, but unlike gonadal dysgenesis in patients with X chromosome abnormalities, these structures carry a high risk for the development of gonadal tumors.23 These tumors may result from the persistence of residual XY germ cells that did not degenerate or from tumorigenic loci on the Y chromosome. Although the presence or absence of the SRY gene determines the differentiation of the bipotential gonad, additional genes that are both autosomal and X-linked and located upstream and downstream from the SRY gene are involved in gonadal development and differentiation (Figure 98-1).64 Several of these genes have in common the encoding of a type of protein that functions as a transcription factor or transcription regulatory protein, which activates or represses the expression of other target genes, often in multiple tissues, thereby influencing or controlling a diverse program of cellular differentiation and proliferation during embryonic and fetal development. When gene mutation occurs, an alteration in the functional domain of the transcription factor can lead to abnormal or changed regulation (e.g., from a repressor to an activator) of downstream genes, resulting in abnormal cell differentiation or growth or neoplastic transformation. It is the occurrence of such mutations and the resulting pathologic conditions that have led to the identification and functional understanding of many of these genes. Examples of gene mutations that affect sex determination in 46,XY and 46,XX patients with DSDs are listed in Table 98-1.64 TABLE 98-1 Examples of Gene Mutations That Affect the Sex Determination, Clinical Phenotype, and Associated Anomalies Modified from Ono M, Harley VR. Disorders of sex development: new genes, new concepts. Nat Rev Endocrinol. 2013;9:79-91. The gonadal blastema begins to form at 4 to weeks in the genital ridge, located bilaterally on the medial aspect of each mesonephros. The somatic component of the gonad is made up of cells from the coelomic epithelium and the underlying mesenchyme or adjacent mesonephros.75 The germinal component comprises the primordial germ cells, which are mitotically active and migrate from the yolk sac endoderm at 24 days to reach the genital ridge at to 6 weeks, thereby forming the indifferent gonad (Figure 98-2).53 Sex differentiation of the gonad begins at 7 weeks and denotes the onset of fetal sexual differentiation. The gonad differentiates as a testis if the SRY gene and its pathway are present and as an ovary if it is absent. The sex differences that appear in the developing gonad at this time include differentiation of cord somatic cells, changes in germ cell mitotic and meiotic activity, hormone production by the cord and interstitial (mesenchymal) cells, and development of the outer cortex. These differences are detailed in Table 98-2, and an overview is schematically represented in Figure 98-2. TABLE 98-2 Descriptive Features of Testicular and Ovarian Differentiation at 7 Weeks of Gestation Testicular differentiation begins at 7 to 8 weeks, when the sex cords form loops in the cortex and differentiate as the seminiferous cords; in the hilum, they anastomose to form the rete cords. From 8 weeks on, the seminiferous cords become coiled and thickened and contain 8 to 10 layers of Sertoli cells, whereas the spermatogonia remain located near the basement membrane of the cords. Leydig cells appear in the interstitium between the seminiferous cords at to 8 weeks. They increase strikingly in number during the third month, occupy half the volume of the testis at 13 to 14 weeks, and then show a significant fall in number. Some Leydig cells are present postnatally, but histologically disappear after 3 to 6 months because of the physiologic lowering of gonadotropin stimulation. As the fetus elongates, the testis descends and occupies a more caudal position. In the sixth and seventh months, the cremaster muscle differentiates in the caudal testicular ligament to form the testicular gubernaculum, which penetrates the inguinal canal and is anchored to the connective tissue of the scrotum. The testis descends behind the peritoneum and reaches the scrotum by the eighth or ninth month; the inguinal canal closes after testicular descent is complete.33 Ovarian differentiation begins at 7 weeks, as outlined previously and in Table 98-2. The sex cords in the ovary show germ cells (oogonia) undergoing repeated mitotic divisions from 7 weeks through about the fifth month. Most oogonia differentiate into oocytes between about 10 and 24 weeks; in so doing, they enter meiosis, proceeding through the first meiotic prophase. After reaching the meiotic prophase, many oocytes become surrounded by a single layer of granulosa cells to form the primordial follicles from about 15 weeks through term. Two X chromosomes are needed for differentiation of the primordial follicle. Oocytes degenerate if they are not enclosed in a follicle. During ovarian differentiation, the number of germ cells greatly increases to several million oogonia and oocytes by the fifth month. Most germ cells degenerate thereafter either before or during the primordial follicle stage, leaving about 150,000 oocytes in each ovary at birth.89 In the male fetus, the müllerian ducts begin to regress at 7 to weeks, shortly after the Sertoli cells have differentiated and begun to produce anti-müllerian hormone (AMH), otherwise known as müllerian-inhibiting substance (MIS), and before the onset of local testosterone production by Leydig cells. Regression is complete by 9 weeks. Differentiation of the wolffian ducts is testosterone dependent and begins at about weeks. The wolffian ducts differentiate into the epididymis and vas deferens, and beginning at weeks, the seminal vesicles and their ejaculatory ducts develop at the caudal end from lateral outpouchings (Figure 98-3). In the female fetus, müllerian duct differentiation occurs in the absence of AMH and does not require the presence of any ovarian hormone. The müllerian ducts form the fallopian tubes, uterus, and upper portion of the vagina beginning in the third month, stimulated in part by epidermal growth factor. The wolffian ducts degenerate in the absence of local testosterone and disappear by 13 weeks (see Figure 98-3). The fallopian tubes later descend with the ovaries and are included in a fold of peritoneum called the broad ligament. At birth, the position of the uterus is vertical, and uterine development is disproportionate in that the uterine cervix is twice as large as the fundus; it remains so until puberty. Maternal estrogens stimulate uterine growth in utero, so its size at birth is larger than it is at several months of age; endometrial hyperplasia may occasionally result in transient neonatal uterine bleeding. The development of the vagina depends on the caudal müllerian ducts’ contacting the endodermal epithelium of the urogenital sinus. At this junction, a multilayered, solid epithelial cord known as the vaginal plate is formed; it disintegrates beyond 4 months to form the vaginal lumen. It is not clear whether the lower portion of the vagina is derived from the urogenital sinus, with the upper portion of müllerian origin, or the vagina originates entirely from the urogenital sinus. The external genitalia in both sexes, like the gonads, are derived from common anlagen (Figure 98-4). Their inherent development is along female lines unless systemic androgens, specifically dihydrotestosterone (DHT), induce male differentiation. The genital tubercle forms early in the fourth week at the cranial end of the cloacal membrane, and on each side, the labioscrotal swellings and urogenital folds develop. Fusion of the urorectal septum with the cloacal membrane in the seventh week creates a dorsal anal membrane and a ventral urogenital membrane, which rupture in the eighth week to form the anus and urogenital orifice. Abnormal development of the urorectal septum results in anorectal malformations. In the male fetus, the indifferent stage of the external genitalia lasts until the ninth week when, in the presence of systemic androgens, masculinization begins with lengthening of the anogenital distance (see Figure 98-4). The urogenital and labioscrotal folds fuse in the midline, beginning caudally and progressing anteriorly. The urethra develops with fusion of the urogenital folds, which form both the membranous urethra in the perineum and the penile urethra along the ventral surface of the phallus. Midline fusion of the labioscrotal folds forms the scrotal raphe, whereas the penile raphe represents the fused portions of the urogenital folds. These processes are complete in the 14-week fetus. In the 9-week female fetus, the anogenital distance does not increase, and the urogenital folds and labioscrotal swellings do not fuse (see Figure 98-4). The labioscrotal swellings develop predominantly in their caudal portions but less so than in male fetuses and they remain unfused as they are transformed into the labia majora. The urogenital folds develop into the labia minora. The epithelium of the vaginal vestibule between the labia minora and the hymen is endodermal, being derived from the urogenital sinus, whereas the epithelium between the labia minora and majora is ectodermal in origin.54 The other major hormone produced by the fetal testis is testosterone (Figure 98-5). It is synthesized by the Leydig cells beginning at 8 weeks, and testicular production achieves peak serum testosterone levels at 10 to 15 weeks. In the second half of gestation, males show a gradual decline and females a rise in serum testosterone levels, so by the third trimester, males have similar or only slightly higher levels than females.79 The control of the fetal testicular synthesis of testosterone between 8 and 14 weeks is under human chorionic gonadotropin (hCG) of placental or fetal origin, which binds to fetal testes beginning at 8 weeks. In the second and third trimesters, fetal serum luteinizing hormone (LH) levels correlate with the maintenance and subsequent decline of serum testosterone.6 Follicle-stimulating hormone (FSH) receptors are present in fetal testes from 8 weeks on and may play a role in Sertoli cell or seminiferous tubule development. The fetal ovary in the first trimester is hormonally quiescent, lacking hCG and FSH binding and the enzymes necessary for steroid synthesis. Starting at 8 weeks, the fetal ovary has aromatase activity and is capable of converting androstenedione or testosterone to estrone or estradiol, but actual production has not been demonstrated. Most estrogen that is present in the fetus is produced by placental aromatase. Amniotic fluid levels of estradiol at 12 to 16 weeks are slightly higher in females, raising the possibility of ovarian synthesis of estrogen. If it is synthesized, estradiol could play a local role in ovarian differentiation.3 Male sex differentiation requires bilateral testes that produce AMH from the Sertoli cell and testosterone from the Leydig cells. Antimüllerian hormone acts locally to cause regression of only the ipsilateral müllerian duct. If only one testis is present, müllerian duct development occurs on the contralateral side. Testosterone does not cause müllerian duct regression. A 46,XX female with müllerian duct regression resulting from a WNT4 mutation suggests that müllerian duct regression can be controlled by proteins other than AMH.32 Most individuals with a DSD have some abnormality of their external genitalia that makes them identifiable at birth. An evaluation of a DSD is needed for patients who have male-appearing external genitalia with defects including isolated micropenis, severe hypospadias (perineal), bilateral cryptorchidism, or the presence of two defects such as hypospadias and unilateral cryptorchidism. In an infant with female-appearing external genitalia, the presence of posterior labial fusion, clitoromegaly, and labial or inguinal mass that might represent a gonad warrant evaluation for possible DSD, as does the finding of discordance of the prenatal karyotype with postnatal external genital phenotype.41 Examples of conditions that can cause genital abnormalities are listed in Table 98-3. TABLE 98-3 Associations of Genital Abnormalities Most DSDs are isolated occurrences or inherited as an autosomal recessive or X-linked trait. The family may not know the specifics about other family members with DSDs but may be aware of a family history of a trait that could be a manifestation of a DSD such as infertility, amenorrhea, or hypospadias or infants with unexplained deaths in the family. History of parental consanguinity, maternal intake of drugs during pregnancy (such as androgen or progestins), use of assisted reproductive technologies, and the results of prenatal tests should be explored. A history of maternal virilization during pregnancy, especially if assessing a virilized female infant, raises the possibility of aromatase deficiency or maternal androgen-secreting tumors such as luteoma.86 Considerable information can be obtained by performing a careful physical examination. The findings of a normal newborn external genital examination are listed in Box 98-1. The clinical findings do not need to be overtly ambiguous to qualify for a diagnostic evaluation for DSDs. Inferences can be made regarding gonadal development and status and the degree of androgen effects. When evaluating a newborn for possible DSD, the clinical features of the external genitalia that require examination include evidence for any asymmetry, presence of palpable gonads in the labioscrotal folds, pigmentation and extent of labioscrotal folds fusion and rugosity, phallus length, breadth, and amount of erectile tissue, number of orifices in the perineum and their topography and the position and patency of the anus (Table 98-4). A useful tool to describe and grade the extent of female external genitalia virilization can be done using Prader scale (Stage I-V) (Figure 98-6), whereas calculating the external masculinization score (EMS: scale 0-12) provides an objective aggregate score to describe the extent of masculinization of external genitalia in boys (Figure 98-7).22 TABLE 98-4 Initial Assessment of Disorder of Sex Development in the Newborn It is important to assess both the length and the amount of erectile tissue of the penis. A penis that appears small must be measured fully stretched, pressing the ruler down against the pubic ramus, depressing the suprapubic fat pad completely, and measuring to the tip of the glans only, ignoring any excess foreskin (Figure 98-8). An excellent ruler can be made by placing marks 0.5 cm apart on a wooden stick such as a tongue blade or a flexible strip. The width is measured at the midshaft of the stretched penis. A micropenis is arbitrarily defined as a penis with a normally formed urethra that opens at the tip of the glans in which the stretched length is less than 2.5 cm in the full-term neonate. The length criteria must be adjusted to take into account the smaller phallus in the premature neonate (Figure 98-9).25 The definition of a micropenis can also be used to describe a rare condition in which the penile corpora cavernosa are absent or severely deficient in size, resulting in an abnormally thin penis (Table 98-5).41 TABLE 98-5 Anthropometric Measurements of the External Genitalia Data from Lee PA; International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 2006;118:e488. A clitoris that appears enlarged is best assessed by measurement of the width (diameter) of the paired corpora cavernosa that compose the erectile shaft of the clitoris. With clitoral enlargement caused by edema or birth trauma, a normal corporal width (<6 mm) is present, whereas clitoral enlargement caused by androgen stimulation (occurring in the second and third trimesters) results in increased corporal growth (>6 mm). The width of the clitoris is measured by gently but firmly pressing the shaft of the clitoris between the thumb and forefinger to exclude excess skin and subcutaneous tissue, thereby measuring predominantly the width of the corpora cavernosa.61 The male fetal urethral development is a hormone-dependent process that occurs at 8 to 14 weeks of gestation. During this stage, testosterone secretion is stimulated solely by the placental hCG. The main hormone involved in urethral development is DHT, which is produced from testosterone in a process catalyzed by 5α-reductase. If the foreskin is fully formed, the urethra is almost always at the tip of the glans; on rare occasions, the foreskin covers hypospadias on the glans. Hypospadias can vary from mild (off the center of the glans) to severe (at the base of the penis or on the perineum) (Figure 98-10). The prepuce in the hypospadiac penis is usually deficient ventrally and thus appears hooded. Chordee (ventral curvature of the penis) is caused by fibrotic contracture in the area of failed urethral development. The presence of severe hypospadias in a male infant indicates deficient testosterone or DHT action in the first trimester. In girls, the urethral meatus is normally a 1-mm pinhole-like or flat opening located just ventral to the vagina. Androgen exposure at 8 to 14 weeks of fetal age moves the urethral meatus ventrally on the perineum or the shaft of the phallic structure. Following are examples of scripts for answering questions commonly asked by families with children with a new diagnosis of a DSD. These are taken largely from the Clinical Guideline for the Management of DSD in Childhood, published by the Consortium on the Management of Disorders of Sex Development.34 Q: Is my child a boy or a girl? Q: What do we tell our friends and family while we wait for the gender assignment? Because of the stress produced by having a child with DSD, support from a behavioral scientist (social worker, psychologist, or psychiatrist) may be helpful for the family. It may be helpful for families to be informed about relevant credible resources listed at the end of this section.41 In cases in which gender assignment is pending, all relevant tests should be obtained as soon as possible. A summary of the initial workup for DSD evaluation in newborns is shown in Box 98-2. Interpretation of biochemistry tests is dependent on the timing of the sample and understanding of the normal levels of hormones at that time. A blood sample should be obtained after 24 to 48 hours of life, after the time of the neonatal surge of androgens, for measurement of testosterone and 17-hydroxyprogesterone (17-OHP). It is desirable to draw extra blood so that the laboratory can save the serum for analysis of other hormones that may be indicated as the evaluation continues. Increased serum levels of testosterone occur physiologically in neonates with functioning testes at 12 to 36 hours and at 2 weeks to 4 to 6 months of age.88 The level may also increase pathologically at any time from the adrenal secretion of androgens in cases of CAH. Decreased levels of testosterone occur if Leydig cells are deficient or absent, LH activity is impaired, or there is a testosterone biosynthetic defect. Blood samples are also diagnostically useful at 1 or 2 months of age to assess the peak of hypothalamic-pituitary-testicular axis function in infancy. An increased level of 17-OHP suggests 21- or 11β-hydroxylase deficiency and implies that any increased levels of testosterone were of adrenal rather than testicular origin in a 46,XX patient. The 17-OHP levels in premature infants are higher than those in full-term infants.40 In CAH with 21-hydroxylase deficiency, the levels of 17-OHP are often 10 to 50 times the upper limit of the normal level, making the test virtually diagnostic. The measurement of serum AMH has been shown to correlate with Sertoli cell function.8 Similarly, inhibin B levels have been shown to rise in males in the first week of life. Its measurement is therefore useful for identifying the presence of Sertoli cells and of functional testes in newborn boys with nonpalpable gonads.8 Other tests that may be useful, depending on the clinical presentation, are measurements of LH, FSH, estradiol, precursors of testosterone, and DHT.
Disorders of Sex Development
Fetal Sexual Determination and Differentiation
Genetic Control of Fetal Gonadal Determination and Differentiation
Sex Chromosomes and Role of the SRY Gene
Autosomal and X-Linked Genes
Gene (Locus)
Gonadal Development and External Genital Phenotype(s)
Müllerian Structures
Associated Disorders
Gene Mutations Described in 46,XY DSD
WT1 (WT33)
(11p13)
Dysgenetic testis
Undervirilized ; EG or normal ; EG
±
Wilms tumor, renal abnormalities, gonadal tumors (WAGR, Denys-Drash, and Fraser syndromes)
MAP3K1
(5q11.2)
Dysgenetic testis
Normal/undervirilized ; EG or normal ; EG
±
None
ARX
(Xp22.13)
Dysgenetic testis
Undervirilized ; EG
−
Lissencephaly, epilepsy, temperature instability
ATRX
(Xq13.3)
Dysgenetic testis
Normal/undervirilized ; EG or normal ; EG
−
α-Thalassemia, developmental delay, dysmorphic facial features
WWOX
(16q23.3-q24.1)
Dysgenetic testis
Normal ; EG
−
—
AMH or Type II receptors
(19p13.3-13.2)
(12q12-13)
Normal gonadal development
Normal ; EG
+
—
NROB1 (DAX1)
(Xp21.3)
Dysgenetic testis
Normal/undervirilized ; EG or normal ; EG
±
Congenital adrenal hypoplasia, hypogonadotrophic hypogonadism
DHH
(12q13.1)
Dysgenetic testis
Normal ; EG
+
Minifascicular neuropathy
DMRT1
(9p24.3)
Dysgenetic testis
Normal/undervirilized ; EG
±
Facial abnormality, developmental delay, microcephaly
CBX2
(17q25)
Normal ovaries
Normal ; EG
+
None
GATA4
(8p23.1– p22)
Dysgenetic testis
Normal/undervirilized ; EG
−
Congenital heart disease
AR
(Xq12)
Normal/undervirilized ; EG or
normal ; EG
−
Spinal and bulbar muscular atrophy (SBMA) and prostate cancer
Gene Mutations Described in 46,XX DSD
SOX3 duplication
(Xq27.1)
Atrophic change in testis with loss of normal spermatogenesis
Normal/virilized ; EG
Data unavailable
Microcephaly, developmental delay, growth restriction
RSPO1
(1p34.3)
Testis or ovotestis
Virilized ; EG or undervirilized ; EG
−
Palmoplantar hyperkeratosis, squamous cell carcinoma of the skin
Gene Mutations Described in 46,XY or 46,XX DSDs
SOX9 duplication
(17q24q25)
46,XY DSD:
Dysgenetic testis or ovotestis
±
Camptomelic dysplasia
Undervirilized ; EG or normal ; EG
46,XX DSD:
−
Gonadal histologic phenotype: not determined
None
Virilized ; EG or undervirilized ; EG
SRY translocation
(Yp11.3)
46,XY DSD:
Dysgenetic testis or ovotestis
±
None
Undervirilized ; EG or normal ;
EG
−
46,XX DSD:
None
Testis or ovotestis
MAMLD1
(Xq28)
46,XY DSD:
Isolated hypospadias
−
None
46,XX DSD:
Streak or dysgenetic gonads
+
None
Abnormal ; EG
NR5A1
(SF-1)
(9p33)
46,XY DSD:
Dysgenetic testis
±
± Adrenal insufficiency
Normal/undervirilized ; EG or
normal ; EG
46,XX DSD:
Dysgenetic gonads
+
None
Normal ; EG
WNT4
(1p35)
46,XY DSD:
−
Cleft lip, cleft palate, IUGR, tetralogy of Fallot, developmental delay, microcephaly
Dysgenetic testis
Undervirilized ; EG
46,XX DSD:
−
Ovary or ovotestis
Normal/virilized ; EG or normal ; EG
Mayer-Rokitansky-Küster-Hauser, SERKAL syndromes
Embryology and Endocrinology
Development of the Gonads
Gonadal Cells
Testicular Differentiation
Ovarian Differentiation
Cord somatic cells
Differentiate as Sertoli cells
Differentiate as granulosa cells
Synthesize antimüllerian hormone (AMH) at weeks
Do not synthesize AMH at this age
Unable to aromatize androgens to estrogens
Able to aromatize androgens to estrogens
Germ cells
Reduced mitotic activity results in small number of spermatogonia
High mitotic activity results in large number of oogonia
Meiosis is inhibited until puberty
Meiosis is promoted within several weeks
Interstitial cells
Differentiate as Leydig cells
Remain undifferentiated until 15 weeks
Synthesize testosterone de novo at 8 weeks
Lack steroidogenic capability at this age
Outer cortex
Sex cords lose connection with surface epithelium
Sex cords retain connection with surface epithelium
Mesenchymal tissue forms tunica albuginea that lacks germ cells
Thickened zone that contains germ cells
Testicular Differentiation
Ovarian Differentiation
Development of the Genital Ducts
Development of the External Genitalia
Hormonal Control of Fetal Sex Differentiation
Fetal Gonadal Endocrine Function
Control of Genital Differentiation: Roles of Antimüllerian Hormone and Testosterone
A Clinical Approach to the Infant with Suspected Disorder of Sex Development
Clinical Indications for Disorder of Sex Development Evaluation
Abnormal Characteristics
Examples of Associated Disorders
Male-Appearing Genitalia
Micropenis
Growth hormone or luteinizing hormone deficiency
Testosterone deficiency (in second and third trimesters)
Partial androgen insensitivity
Syndrome: idiopathic
Hypospadias (more severe)
Disorders of gonadal development
46,XX DSD
Ovotesticular DSD
46,XX or 46,XX DSD
Syndrome: idiopathic
Impalpable gonads
Anorchia
Persistent müllerian duct syndrome
46,XX DSD with 21- or 11β-hydroxylase deficiency
Cryptorchidism
Small gonads
47,XXY, 46,XX DSD
Dysgenetic or rudimentary testes
Inguinal mass (uterus or tube)
Persistent müllerian duct syndrome, dysgenetic testes
Female-Appearing Genitalia
Clitoromegaly
XX with 21- or 11β-hydroxylase or 3β-hydroxy dehydrogenase deficiency
Other 46,XX DSD
Gonadal dysgenesis, dysgenetic testes, ovotesticular DSD
46,XY DSD
Tumor infiltration of clitoris
Syndrome: idiopathic
Posterior labial fusion
As for clitoromegaly
Palpable gonad(s)
Gonadal dysgenesis, dysgenetic testes, ovotesticular DSD
46,XY DSD
Inguinal hernia or mass
As for palpable gonad(s)
History
Physical Examination
History
Maternal History
Virilization during pregnancy, antenatal exposure to drugs (progestins and steroids), assisted reproductive technologies
Perinatal History
Prematurity, intrauterine growth restriction, results of prenatal investigations
Family History
Parental consanguinity, unexplained infant death, infertility, amenorrhea, gonadal or urogenital malformation
Physical examination
General
Signs of dysmorphic features, hyperpigmentation, associated anomalies including skeletal malformations
External Genitalia
Symmetry of virilization
Gonads: location and size
Phallic structure: stretched length, breadth and amount of erectile (corpora) tissue
Labioscrotal folds: degree of fusion, rugation and pigmentation
Perineal orifices: number and topography
Anus: patency and anogenital distance
Prader Classification
Commonly used to stage virilization of female external genitalia (see Figure 98-6)
External Masculinization Score
Helpful tool to grade male masculinization (see Figure 98-7)
Penis Size
Sex
Population
Age
Stretched Penile Length, Mean ± SD, cm (Males), or Clitoral Length, Mean ± SD, mm (Females)
Penile Width, Mean ± SD, cm (Males), or Clitoral Width, Mean ± SD, mm (Females)
Mean Testicular Volume, mL (Males), or Perineum Length, Mean ± SD, mm (Females)
M
United States
30 weeks’ GA
2.5 ± 0.4
M
United States
Term
3.5 ± 0.4
1.1 ± 0.1
0.52 (median)
M
Japan
Term to 14 years
2.9 ± 0.4 − 8.3 ± 0.8
M
Australia
24-36 weeks’ GA
2.27 ± (0.16 GA)
M
China
Term
3.1 ± 0.3
1.07 ± 0.09
M
India
Term
3.6 ± 0.4
1.14 ± 0.07
M
North America
Term
3.4 ± 0.3
1.13 ± 0.08
M
Europe
10 years
6.4 ± 0.4
0.95-1.20
M
Europe
Adult
13.3 ± 1.6
16.5-18.2
F
United States
Term
4.0 ± 1.24
3.32 ± 0.78
F
United States
Adult nulliparous
15.4 ± 4.3
F
United States
Adult
19.1 ± 8.7
5.5 ± 1.7
31.3 ± 8.5
Clitoris Size
Urethral Opening
Discussion with Family and Professional Staff
Initial Diagnostic Evaluation
Biochemistry
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree